title: [New drugs; palifermin].
abstract: Palifermin is a human keratinocyte growth factor that is produced in Escherichia coli by recombinant-DNA-technology. This substance protects against oral mucositis in adults undergoing myeloablative therapy. The safety of this product--being a growth factor --in the long term has not yet been shown. Adverse effects may occur in the skin and mucous membranes.
authors.affiliation: Centre for Human Drug Research, Zernikedreef 10, 2333 CL Leiden. ac@chdr.nl
authors.forename: A F
authors.initials: AF
authors.lastname: Cohen
authors.forename: E A
authors.initials: EA
authors.lastname: Dubois
authors.forename: H
authors.initials: H
authors.lastname: van Bronswijk
mesh_terms: D051523:Fibroblast Growth Factor 7 / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D052016:Mucositis / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety
chemical_list: D011994:Recombinant Proteins; D051523:Fibroblast Growth Factor 7